Two Sigma Investments
GTBP icon

Two Sigma Investments’s GT Biopharma GTBP Stock Holding History

Two Sigma Investments’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,003
Closed -$549K – 3343
2021
Q4 		$549K Buy
6,003
+576
+11% +$86.2K ﹤0.01% 3160
2021
Q3 		$1.1M Buy
+5,427
New +$1.63M ﹤0.01% 2536

Other funds holding GTBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Investments's GTBP Position: Q1 2022 in Review

Two Sigma Investments sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 6,003 shares — an estimated $549K sold.

Two Sigma Investments first reported a position in GTBP in Q3 2021 and held it in 2 quarters. The position peaked at $1.1M in Q3 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

  • Two Sigma Investments reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Investments sold 6,003 GT Biopharma shares in Q1 2022, an estimated $549K.
  • Two Sigma Investments first reported a position in GT Biopharma in Q3 2021 and held it in 2 quarters.
  • Two Sigma Investments's GT Biopharma position peaked at $1.1M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.